Inhibitors of insulin-like growth factor-1 receptor tyrosine kinase are preferentially cytotoxic to nutrient-deprived pancreatic cancer cells

Biochemical and Biophysical Research Communications

Volumn 380, Issue 1, 2009, Pages 171-176

  Momose, Isao ^a   Kunimoto, Setsuko ^a   Osono, Michiyo ^a   Ikeda, Daishiro ^a  

^a Numazu Bio Medical Research Institute   (Japan)

Author keywords

AG1024; IGF 1R; IGF 1R kinase inhibitor; Nutrient starvation; Pancreatic cancer

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; AG 538; ANTINEOPLASTIC AGENT; DOXORUBICIN; FLUOROURACIL; PACLITAXEL; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG INHIBITION; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, IGF TYPE 1; TYRPHOSTINS;

EID: 59649111113     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.01.065     Document Type: Article

References (35)

1. Li D., Xie K., Wolff R., and Abbruzzese J.L. Pancreatic cancer. Lancet 363 (2004) 1049-1057
2. Shore S., Vimalachandran D., Raraty M.G., and Ghaneh P. Cancer in the elderly: pancreatic cancer. Surg. Oncol. 13 (2004) 201-210
3. Izuishi K., Kato K., Ogura T., Kinoshita T., and Esumi H. Remarkable tolerance of tumor cells to nutrient deprivation: possible new biochemical target for cancer therapy. Cancer Res. 60 (2000) 6201-6207
4. Lu J., Kunimoto S., Yamazaki Y., Kaminishi M., Esumi H., and Kigamicin D. A novel anticancer agent based on a new anti-austerity strategy targeting cancer cells' tolerance to nutrient starvation. Cancer Sci. 95 (2004) 547-552
5. Kunimoto S., Lu J., Esumi H., Yamazaki Y., Kinoshita N., Honma Y., Hamada M., Ohsono M., Ishizuka M., Takeuchi T., and Kigamicins D. Novel antitumor antibiotics. I. Taxonomy, isolation, physico-chemical properties and biological activities. J. Antibiot. 56 (2003) 1004-1011
6. Kunimoto S., Someno T., Yamazaki Y., Lu J., Esumi H., Naganawa H., and Kigamicins D. Novel antitumor antibiotics. II. Structure determination. J. Antibiot. 56 (2003) 1007-1012
7. Esumi H., Lu J., Kurashima Y., and Hanaoka T. Antitumor activity of pyrvinium pamoate, 6-(dimethylamino)-2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methyl-quinolinium pamoate salt, showing preferential cytotoxicity during glucose starvation. Cancer Sci. 95 (2004) 685-690
8. Pollak M.N., Schernhammer E.S., and Hankinson S.E. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4 (2004) 505-518
9. Ullricha A., and Schlessingerb J. Signal transduction by receptors with tyrosine kinase activity. Cell 61 (1990) 203-212
10. Geer P.V.D., Hunter T., and Lindberg R.A. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu. Rev. Cell Biol. 10 (1994) 251-337
11. Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19 (2000) 5574-5581
12. Bohula E.A., Salisbury A.J., Sohail M., Playford M.P., Riedemann J., Southern E.M., and Macaulay V.M. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J. Biol. Chem. 278 (2003) 15991-15997
13. Maloney E.K., McLaughlin J.L., Dagdigian N.E., Garrett L.M., Connors K.M., Zhou X.-M., Blättler W.A., Chittenden T., and Singh R. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 63 (2003) 5073-5083
14. Burtrum D., Zhu Z., Lu D., Anderson D.M., Prewett M., Pereira D.S., Bassi R., Abdullah R., Hooper A.T., Koo H., Jimenez X., Johnson D., Apblett R., Kussie P., Bohlen P., Witte L., Hicklin D.J., and Ludwig D.L. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 63 (2003) 8912-8921
15. Hayry P., Myllarniemi M., Aavik E., Alatalo S., Aho P., Yilmaz S., Sokolowski A.R., Cozzone G., Jameson B., and Baserga R. Stabile d-peptide analog of insulin-like growth factor-1 inhibits smooth muscle cell proliferation after carotid ballooning injury in the rat. FASEB J. 9 (1995) 1336-1344
16. Sachdev D., Hartell J.S., Lee A.V., Zhang X., and Yee D. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J. Biol. Chem. 279 (2004) 5017-5024
17. Lee C.-T., Park K.-H., Adachi Y., Seol J.Y., Yoo C.-G., Kim Y.W., Han S.K., Shim Y.-S., Coffee K., Dikov M.M., and Carbone D.P. Recombinant adenoviruses expressing dominant negative insulin-like growth factor-I receptor demonstrate antitumor effects on lung cancer. Cancer Gene. Ther. 10 (2003) 57-63
18. Min Y., Adachi Y., Yamamoto H., Ito H., Itoh F., Lee C.-T., Nadaf S., Carbone D.P., and Imai K. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. Cancer Res. 63 (2003) 6432-6441
19. García-Echeverría C., Pearson M.A., Marti A., Meyer T., Mestan J., Zimmermann J., Gao J., Brueggen J., Capraro H.-G., Cozens R., Evans D.B., Fabbro D., Furet P., Porta D.G., Liebetanz J., Martiny-Baron G., Ruetz S., and Hofmann F. In vivo antitumor activity of NVP-AEW541-a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5 (2004) 231-239
20. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Shringarpure R., Akiyama M., Hideshima T., Chauhan D., Joseph M., Libermann T.A., García-Echeverría C., Pearson M.A., Hofmann F., Anderson K.C., and Kung A.L. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5 (2004) 221-230
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983) 55-63
22. Wen B., Deutsch E., Marngoni E., Frascona V., Maggiorella L., Abdulkarim B., Chavaudra N., and Bourhis J. Tyrphostin AG 1024 modulates rediosensitivity in human breast cancer cells. Br. J. Cancer 85 (2001) 2017-2021
23. Blum G., Gazit A., and Levitzki A. Substrate competitive inhibitors of IGF-1 receptor kinase. Biochemistry 39 (2000) 15705-15712
24. Strawn L.M., McMahon G., App H., Schreck R., Kuchler W.R., Longhi M.P., Hui T.H., Tang C., Levitzki A., Gazit A., Chen I., Keri G., Orfi L., Risau W., Flamme I., Ullrich A., Hirth K.P., and Shawver L.K. Flk-1 as a target for tumor growth inhibition. Cancer Res. 56 (1996) 3540-3545
25. Levitzki A., and Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 267 (1995) 1782-1788
26. Bose R., Molina H., Patterson A.S., Bitok J.K., Periaswamy B., Bader J.S., Pandey A., and Cole P.A. Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc. Natl. Acad. Sci. USA 103 (2006) 9773-9778
27. Fry D.W., Bridges A.J., Denny W.A., Doherty A., Greis K.D., Hicks J.L., Hook K.E., Keller P.R., Leopold W.R., Loo J.A., McNamara D.J., Nelson J.M., Sherwood V., Smaill J.B., Trumpp-Kallmeyer S., and Dobrusin E.M. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA 95 (1998) 12022-12027
28. Dang C.V., and Semenza G.L. Oncogenic alterations of metabolism. Trends Biochem. Sci. 24 (1999) 68-72
29. Southerland R.M. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240 (1988) 178-184
30. 2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat. Med. 3 (1997) 177-182
31. Marcelina P., Aviv G., Alexander L., Efrat W., and Derek L. Specific inhibitor of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 138 (1997) 1427-1433
32. Awale S., Li F., Onozuka H., Esumi H., Tezuka Y., and Kadota S. Constituents of Brazilian red propolis and their preferential cytotoxic activity against human pancreatic PANC-1 cancer cell line in nutrient-deprived condition. Bioorg. Med. Chem. 16 (2008) 181-189
33. Toker A., and Yoeli-Lerner M. Akt signaling and cancer: surviving but not moving on. Cancer Res. 66 (2006) 3963-3966
34. Bader A.G., Kang S., Zhao L., and Vogt P.K. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 5 (2005) 921-929
35. Meuillet E.J., Ihle N., Baker A.F., Gard J.M., Stamper C., Williams R., Coon A., Mahadevan D., George B.L., Kirkpatrick L., and Powis G. In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316. Oncol. Res. 14 (2004) 513-527